Publications
Specialty
Search
EP Lab Digest
08/30/2024
Alnylam Pharmaceuticals Press Release
CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
EP Lab Digest
08/30/2024
CE mark of these next-generation cardiac imaging systems will further enable connected care along the cardiology patient journey and provide clinicians with the tools to deliver more efficient and timely care
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/30/2024
Peripheral arterial and aortic diseases (PAAD) is estimated to affect around 113 million people aged 40 and over globally. "The aorta and peripheral arteries are integral components of the same arterial system. Disorders in one part of this system often have implications for the other,” notes Professor Lucia Mazzolai.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/30/2024
The ABYSS trial suggests that long-term beta-blocker therapy is recommended after an MI, even in the absence of heart failure, arrhythmia or uncontrolled hypertension.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/30/2024
“The new guidelines prompt cardiologists to rethink chronic coronary syndromes as caused not only by blockages in large arteries but also by dysfunction of smaller vessels (microcirculation),” explains Guidelines co-chair Professor Christiaan Vrints.
EMSWorld
08/30/2024
'Just Say No' is sadly not always enough. Get a glimpse into the future as it pertains to keeping our pediatric patients safe.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
08/30/2024
Whereas prior guidelines generally recommended patients be treated to a BP
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/30/2024
“This Consensus Statement aims to raise awareness on obesity as a major risk factor and provide guidance for implementing evidence-based practices for its prevention and optimal management within the context of primary and secondary CVD prevention,” says Professor Eva Prescott.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/30/2024
In the study, treatment with vutrisiran substantially reduced the risk of death and cardiovascular events relative to placebo.
Psych Congress NP Institute
08/30/2024
Nurse Practitioner Amber Hoberg, MSN, APRN, PMHNP-BC, provides insights on identifying when antidepressants may cease to be effective and offers practical strategies for adjusting treatment.
Oncology
08/30/2024
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes compared to CAR T-cell therapy.
Oncology
08/30/2024
According to results from the phase 3 LITESPARK-005 trial, belzutifan significantly improved progression-free survival and overall response among patients with advanced clear-cell renal cell carcinoma, previously treated with immune checkpoint and antiangiogenic therapies.
Oncology
08/30/2024
According to phase 1/2 results from the AUGMENT study, revumenib, an inhibitor of the menin-lysine methyltransferase 2A interaction, demonstrated high remission rates with a predictable safety profile among patients with relapsed/refractory KMT2Ar acute leukemia.
Rheumatology & Arthritis
08/30/2024
Is there any association between nonsteroidal anti-inflammatory drugs (NSAIDs), axial spondyloarthritis (axSpA), and risk
First Report Managed Care
08/29/2024
Learn about key factors influencing the 2025 Medicare Advantage open enrollment period including payment rate adjustments, compliance regulations, behavioral health benefits, and the importance of hyper-personalization for enhancing customer experience.
Oncology
08/29/2024
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
08/29/2024
In a large international registry study of patients with coronary artery disease, those who quit smoking in the stable period of the disease benefitted from a 44% reduction in the risk of major cardiovascular events, including death or myocardial infarction, over a 5-year follow-up period.
Oncology
08/29/2024
According to results from a univariable and multivariable analysis, undergoing lymph node dissection at the time of hysterectomy improved overall survival among patients with stage 3 endometrial cancer.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
08/29/2024
The UK Biobank study of more than 90,000 individuals showed that those who had the most catch-up sleep on weekends had a 20% lower risk of developing heart disease than those with the least.
Cath Lab Digest, CardioVascular, Journal of Invasive Cardiology
08/29/2024
"One in 3 women die from CVD and 1 in 10 women suffer from endometriosis. Our results suggest that it may be time to routinely consider the risk of CVD in women with endometriosis,” said lead study author Dr. Eva Havers-Borgersen.